Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 16/20 | 0.51 |
| ▸ | AKT2 | P31751 | 16/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1351692 | 0.92 | AKT1 (0.56) | AKT1AKT2CYP11B1CYP11B2MEN1 | |
| Trifluoroacetic Acid SCHEMBL1352465 | 0.82 | AKT1 (0.50) | AKT1AKT2 | |
| SCHEMBL1351207 | 0.82 | AKT1 (0.44) | AKT1AKT2CYP11B1CYP11B2MEN1 | |
| Trifluoroacetic Acid SCHEMBL1350248 | 0.81 | AKT1 (0.48) | AKT1AKT2 | |
| Trifluoroacetic Acid SCHEMBL1351970 | 0.81 | FGFR1 (0.53) | AKT1AKT2 | |
| Trifluoroacetic Acid SCHEMBL1352082 | 0.81 | AKT1 (0.53) | AKT1AKT2 | |
| Trifluoroacetic Acid SCHEMBL1352096 | 0.80 | AKT1 (0.57) | AKT1AKT2 | |
| Trifluoroacetic Acid SCHEMBL1351194 | 0.80 | AKT1 (0.56) | AKT1AKT2 | |
| Trifluoroacetic Acid SCHEMBL1351873 | 0.79 | AKT1 (0.53) | AKT1AKT2 | |
| Trifluoroacetic Acid SCHEMBL1351923 | 0.78 | AKT1 (0.49) | AKT1AKT2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391623-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110288090-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2011-11-24 | — | — | US | disclosed |
| WO-2010088177-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288090-A1 | Inhibitors of AKT Activity | PIK3CD, PIK3CA, PIK3CG | AKT1 9/4885AKT2 5/4885CYP11B1 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.